Guangzhou Institute Of Respiratory Disease
Clinical trials sponsored by Guangzhou Institute Of Respiratory Disease, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cloud tool aims to predict dangerous COPD attacks Results expected Sep 2026 (estimated)
- New drug cocktail aims to stall advanced lung cancer Results expected Dec 2026 (estimated)
-
New drug cocktail aims to stall advanced lung cancer
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of two drugs, lurbinectedin and serplulimab, can help keep extensive-stage small cell lung cancer from growing when used as maintenance therapy after initial chemo-immunotherapy. About 30 adults whose cancer has not worsened aft…
Phase 2 • Sponsor: Guangzhou Institute of Respiratory Disease • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Lab-Grown lung tumors help scientists test new cancer drugs
Knowledge-focused Recruiting nowThis study is testing antibody-drug conjugates (ADCs) on tiny lab-grown versions of lung cancer tumors called organoids. The goal is to understand how these drugs kill cancer cells and interact with the immune system. Researchers will study 10 people with HER2- or TROP2-positive …
Sponsor: Guangzhou Institute of Respiratory Disease • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC